Expression of multidrug resistance-associated proteins and their relation to postoperative individualized chemotherapy in gastric cancer

World Journal of Surgical Oncology

Volumn 12, Issue 1, 2014, Pages

  Yu, Pengfei ^a   Du, Yian ^a   Cheng, Xiangdong ^a   Yu, Qiming ^a   Huang, Ling ^a   Dong, Ruizeng ^a  

^a ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

chemotherapy; multidrug resistance associated proteins; prognosis; stomach neoplasms

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); FLUOROURACIL; GLUTATHIONE TRANSFERASE; MULTIDRUG RESISTANCE PROTEIN; PLATINUM; ANTINEOPLASTIC AGENT; GLUTATHIONE TRANSFERASE P1; GSTP1 PROTEIN, HUMAN; PLATINUM COMPLEX; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; FEMALE; GASTRECTOMY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PERSONALIZED MEDICINE; POSTOPERATIVE PERIOD; PROTEIN EXPRESSION; RECURRENT DISEASE; RISK FACTOR; STOMACH CANCER; SURVIVAL RATE; TUMOR RECURRENCE; ADJUVANT CHEMOTHERAPY; CANCER STAGING; DRUG RESISTANCE; ENZYME IMMUNOASSAY; FOLLOW UP; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; POSTOPERATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDY; STOMACH NEOPLASMS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; GASTRECTOMY; GLUTATHIONE S-TRANSFERASE PI; HUMANS; IMMUNOENZYME TECHNIQUES; INDIVIDUALIZED MEDICINE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; P-GLYCOPROTEIN; POSTOPERATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84908092660     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-12-307     Document Type: Article

References (21)

1. Kodera Y, Ito S, Mochizuki Y, Kondo K, Koshikawa K, Suzuki N, Kojima H, Kojima T, Matsui T, Takase T, Tsuboi K, Fujiwara M, Nakao A. A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG0301 study). Eur J Surg Oncol 2009, 35:1158-1163. 10.1016/j.ejso.2009.03.003, 19328643.
2. Omura T, Shimada Y, Nagata T, Okumura T, Fukuoka J, Yamagishi F, Tajika S, Nakajima S, Kawabe A, Tsukada K. Relapse-associated microRNA in gastric cancer patients after S-1 adjuvant chemotherapy. Oncol Rep 2014, 31:613-618.
3. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzén F. Noh SH; CLASSIC trial investigators: Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012, 379:315-321. 10.1016/S0140-6736(11)61873-4, 22226517.
4. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2012, 29:4387-4393.
5. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J. Kang YK; ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2012, 376:687-697.
6. Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, Zhang S, Lee M, Wu J, Lim KH, Lei Z, Goh G, Lim QY, Tan AL, Sin Poh DY, Riahi S, Bell S, Shi MM, Linnartz R, Zhu F, Yeoh KG, Toh HC, Yong WP, Cheong HC, Rha SY, Boussioutas A, Grabsch H, Rozen S, Tan P. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 2012, 61:673-684. 10.1136/gutjnl-2011-301839, 3322587, 22315472.
7. Liu Y, Chen J, Shao N, Feng Y, Wang Y, Zhang L. Clinical value of hematologic test in predicting tumor response to neoadjuvant chemotherapy with esophageal squamous cell carcinoma. World J Surg Oncol 2014, 12:43. 10.1186/1477-7819-12-43, 3938076, 24568553.
8. Lu D, Shi HC, Wang ZX, Gu XW, Zeng YJ. Multidrug resistance-associated biomarkers PGP, GST-pi, Topo-II and LRP as prognostic factors in primary ovarian carcinoma. Br J Biomed Sci 2011, 68:69-74.
9. Kunjachan S, Rychlik B, Storm G, Kiessling F, Lammers T. Multidrug resistance: Physiological principles and nanomedical solutions. Adv Drug Deliv Rev 2013, 65:1852-1865. 10.1016/j.addr.2013.09.018, 3939439, 24120954.
10. Shi H, Lu D, Shu Y, Shi W, Lu S, Wang K. Expression of multidrug resistance-related proteins P-glycoproteinglutathione-s-transferases, ToPoisomerase-II and Lung resistance protein in primary gastric cardiac adenocarcinoma. Cancer Invest 2008, 26:344-351. 10.1080/07357900701788072, 18443954.
11. Wu Y, Wei ZW, He YL, Schwarz RE, Smith DD, Xia GK, Zhang CH. Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer. World J Gastroenterol 2013, 19:3309-3315. 10.3748/wjg.v19.i21.3309, 3671083, 23745033.
12. Fujitani K. Overview of adjuvant and neoadjuvant therapy for resectable gastric cancer in the East. Dig Surg 2013, 30:119-129. 10.1159/000350877, 23867588.
13. Li Y, Tan BB, Zhao Q, Fan LQ, Liu Y, Hao YJ, Zhao XF. Tumor chemosensitivity is correlated with expression of multidrug resistance associated factors in variously differentiated gastric carcinoma tissues. Hepatogastroenterology 2013, 60:213-216.
14. Zhu CY, Lv YP, Yan DF, Gao FL. Knockdown of MDR1 Increases the Sensitivity to Adriamycin in Drug Resistant Gastric Cancer Cells. Asian Pac J Cancer Prev 2013, 14:6757-6760. 10.7314/APJCP.2013.14.11.6757, 24377601.
15. Xu HW, Xu L, Hao JH, Qin CY, Liu H. Expression of P-glycoprotein and multidrug resistance-associated protein is associated with multidrug resistance in gastric cancer. J Int Med Res 2010, 38:34-42. 10.1177/147323001003800104, 20233511.
16. Ge J, Chen Z, Wu S, Chen J, Li X, Li J, Yin J, Chen Z. Expression levels of insulin-like growth factor-1 and multidrug resistance-associated protein-1 indicate poor prognosis in patients with gastric cancer. Digestion 2009, 80:148-158. 10.1159/000226089, 19713703.
17. Soh Y, Goto S, Kitajima M, Moriyama S, Kotera K, Nakayama T, Nakajima H, Kondo T, Ishimaru T. Nuclear localisation of glutathione S-transferase pi is an evaluation factor for drug resistance in gynaecological cancers. Clin Oncol (R Coll Radiol) 2005, 17:264-270. 10.1016/j.clon.2004.11.008, 15997922.
18. Gate L, Majumdar RS, Lunk A, Tew KD. Influence of glutathione S-transferase pi and p53 expression on tumor frequency and spectrum in mice. Int J Cancer 2005, 113:29-35. 10.1002/ijc.20540, 15386426.
19. Chen W, Qiu J, Shen YM. Topoisomerase IIα, rather than IIβ, is a promising target in development of anti-cancer drugs. Drug Discov Ther 2012, 6:230-237.
20. Chau M, Christensen JL, Ajami AM, Capizzi RL. Amonafide, a topoisomerase II inhibitor, is unaffected by P-glycoprotein-mediated efflux. Leuk Res 2008, 32:465-473. 10.1016/j.leukres.2007.07.017, 17826829.
21. Cao DY, Shen K, Yang JX, Guan J. The expression of MRP, GST-pi, Topo IIalpha and COX-2 in epithelial ovarian cancer and its relationship to drug resistance and prognosis. Zhonghua Yi Xue Za Zhi 2007, 87:1738-1741.